Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression.

Zhang F, Liu B, Wang Z, Yu XJ, Ni QX, Yang WT, Mukaida N, Li YY.

Mol Cancer Res. 2013 Dec;11(12):1508-20. doi: 10.1158/1541-7786.MCR-13-0389. Epub 2013 Oct 28.

3.

Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.

Li YY, Mukaida N.

World J Gastroenterol. 2014 Jul 28;20(28):9392-404. doi: 10.3748/wjg.v20.i28.9392. Review.

4.

Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.

Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD, Taverna P, Bednarski BK, Kim HJ, Baldwin AS, Baines AT.

Cancer Biol Ther. 2013 Jun;14(6):492-501. doi: 10.4161/cbt.24343.

5.

T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug.

Wang Z, Li XM, Shang K, Zhang P, Wang CF, Xin YH, Zhou L, Li YY.

Oncol Rep. 2013 Mar;29(3):1245-51. doi: 10.3892/or.2013.2233. Epub 2013 Jan 11.

PMID:
23314349
6.

MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.

Chang W, Liu M, Xu J, Fu H, Zhou B, Yuan T, Chen P.

Tumour Biol. 2016 Nov;37(11):14813-14824. Epub 2016 Sep 16.

PMID:
27638830
7.

Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis.

Liu B, Wang Z, Li HY, Zhang B, Ping B, Li YY.

Oncol Rep. 2014 Jun;31(6):2625-34. doi: 10.3892/or.2014.3158. Epub 2014 Apr 25.

PMID:
24789328
8.

Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells.

Li YY, Wu Y, Tsuneyama K, Baba T, Mukaida N.

Cancer Sci. 2009 Mar;100(3):396-404. doi: 10.1111/j.1349-7006.2008.01059.x. Epub 2008 Dec 16.

9.

Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor.

Wang C, Li HY, Liu B, Huang S, Wu L, Li YY.

J Surg Res. 2013 Dec;185(2):595-604. doi: 10.1016/j.jss.2013.06.004. Epub 2013 Jun 28.

PMID:
23845873
10.

Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis.

Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N.

Cancer Sci. 2007 Mar;98(3):321-8.

11.

Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability.

Li YY, Wang YY, Taniguchi T, Kawakami T, Baba T, Ishibashi H, Mukaida N.

Int J Cancer. 2010 Jul 15;127(2):474-84. doi: 10.1002/ijc.25048.

12.

Pim-3 contributes to radioresistance through regulation of the cell cycle and DNA damage repair in pancreatic cancer cells.

Chen XY, Wang Z, Li B, Zhang YJ, Li YY.

Biochem Biophys Res Commun. 2016 Apr 22;473(1):296-302. doi: 10.1016/j.bbrc.2016.03.099. Epub 2016 Mar 22.

PMID:
27016481
13.

Identification of a phenanthrene derivative as a potent anticancer drug with Pim kinase inhibitory activity.

Wang YY, Taniguchi T, Baba T, Li YY, Ishibashi H, Mukaida N.

Cancer Sci. 2012 Jan;103(1):107-15. doi: 10.1111/j.1349-7006.2011.02117.x. Epub 2011 Nov 7.

14.

The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.

Deng X, Ewton DZ, Li S, Naqvi A, Mercer SE, Landas S, Friedman E.

Cancer Res. 2006 Apr 15;66(8):4149-58.

15.

Knockdown of Pim-3 suppresses the tumorigenicity of glioblastoma by regulating cell cycle and apoptosis.

Quan J, Zhou L, Qu J.

Cell Mol Biol (Noisy-le-grand). 2015 Mar 9;61(1):42-50.

PMID:
25817345
16.
17.

The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.

Xu D, Allsop SA, Witherspoon SM, Snider JL, Yeh JJ, Fiordalisi JJ, White CD, Williams D, Cox AD, Baines AT.

Carcinogenesis. 2011 Apr;32(4):488-95. doi: 10.1093/carcin/bgr007. Epub 2011 Jan 24.

18.

MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.

Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z, Song Y, Ni QX, Li HY, Mukaida N, Li YY.

Oncotarget. 2015 Jun 10;6(16):14440-55.

19.

PIM kinases: an overview in tumors and recent advances in pancreatic cancer.

Xu J, Zhang T, Wang T, You L, Zhao Y.

Future Oncol. 2014 Apr;10(5):865-76. doi: 10.2217/fon.13.229. Review.

PMID:
24799066
20.

Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.

Song B, Liu XS, Rice SJ, Kuang S, Elzey BD, Konieczny SF, Ratliff TL, Hazbun T, Chiorean EG, Liu X.

Mol Cancer Ther. 2013 Jan;12(1):58-68. doi: 10.1158/1535-7163.MCT-12-0632. Epub 2012 Nov 27.

Supplemental Content

Support Center